drugset / Trial / NCT05980689
Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer
Phase 2
Unknown
33 enrolled
Sun Yat-sen University
Akeso · collabHaplox Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm study to investigate the efficacy and safety of AK104 (an Anti-PD1 and Anti-CTLA4 Bispecific Antibody) and neoadjuvant chemoradiotherapy in patients with pMMR/MSS locally advanced rectal cancer.
Timeline
- Start
- 2023-10-24
- Primary completion
- 2024-06-30
- Completion
- 2025-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | — |
| Background | Capecitabine | Small molecule | 825 mg/m2 | — |
Indications
No indication recorded.